biote (BTMD) Enters Settlement with Founder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Biote Announces Definitive Settlement with Founder
April 29, 2024 4:05 PM EDTCompany to repurchase all of Founders 18.4 million shares at $4.17 per share
IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (NASDAQ: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the Settlement Agreement) that concludes outstanding litigation with Dr. Gary S. Donovitz (Donovitz), founder and stockholder of Biote.
The Settlement Agreement includes a mutual release of all claims relating to litigation between Donovitz and Biote; the... More
